Highly sensitive Bridge-Assay for Measuring Insulin- and IGF1-Receptor Autoantibodies

<strong>Background</strong><br>

Autoantibodies (autoAB) against the insulin receptor (IR) are known to cause a rare form of diabetes, i.e. insulin resistance type B. AutoAB against the structurally and functionally related receptor for insulin-like growth factor-1 (IGF1R) have only recently been described and are implicated in autoimmune diseases. However, the prevalence and clinical importance of these autoAB are not yet fully understood as respective sensitive and non-radioactive test systems for routine use were missing. A reliable assay system for the detection and quantification of these autoAB should be met with highest interest by basic researchers and clinicians alike, especially in the fields of diabetes, growth and cancer research, given the central importance of the insulin and IGF1 hormone axes for controlling growth, glucose metabolism and cell proliferation in humans.<br><br> <strong>Technology</strong><br> Two novel non-radioactive and highly sensitive immunoassays for detection and quantification of autoAB against the IR and IGF1R have been developed. For reasons of sensitivity, specificity and automation, the bridge technology has been chosen as most suitable assay format (see scheme). Using these novel in vitro diagnostica, autoAB against the IR and the IGF1R are detected with an astonishing 10% prevalence in the adult population. Notably, a high proportion of cross-reacting autoAB are found, reacting with similar strength to both the IR and IGF1R. The clinical and diagnostic importance of these results remains to be established in ongoing studies.<br><br> <strong>Benefits</strong><br> <ul> <li>Novel non-radioactive IVD for insulin- and IGF1R autoAB detection <li>Improved differential diagnosis of diabetes or autoimmune diseases <li>Automatable bridge-assay technology of excellent precision <li>Applicable for drug screening affecting growth, diabetes or cancer</ul><br> <strong>IP Rights</strong><br> European patent application (02/2012)<br><br> <strong>Patent Owner</strong><br> Charité-Universitätsmedizin Berlin Ici immunointelligence GmbH

Further Information: PDF

ipal GmbH
Phone: +49 (0)30/2125-4820

Contact
Dr. Dirk Dantz

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All news from this category: Technology Offerings

Back to the Homepage

Comments (0)

Write comment

Latest posts

Seawater as an electrical cable !?

Wireless power transfers in the ocean For drones that can be stationed underwater for the adoption of ICT in mariculture. Associate professor Masaya Tamura, Kousuke Murai (who has completed the…

Rare quadruple-helix DNA found in living human cells with glowing probes

New probes allow scientists to see four-stranded DNA interacting with molecules inside living human cells, unravelling its role in cellular processes. DNA usually forms the classic double helix shape of…

A rift in the retina may help repair the optic nerve

In experiments in mouse tissues and human cells, Johns Hopkins Medicine researchers say they have found that removing a membrane that lines the back of the eye may improve the…

Partners & Sponsors

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close